EPI Health has graciously supported the COVID-19 News and Resource Center.
SECURE-AD (Surveillance Epidemiology of Corona Virus (COVID-19) Under Research Exclusion – Atopic Dermatitis) is a secure, online, de-identified international reporting registry for health care providers to report outcomes of COVID-19 in atopic dermatitis (AD) patients.
Clinicians worldwide are encouraged to report all cases of COVID-19 in their AD patients, treated with or without systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening). The aim is to investigate how factors like the use of systemic immunomodulating therapies, age, gender, and comorbidities impact COVID-19 outcomes. This information will be vital for informing assessments of risk of COVID-19 in individuals who are treated with systemic immunomodulation medication and for guiding clinical decision making around their treatments.
The SECURE-AD registry is matched with SECURE-Alopecia and closely aligned to PsoProtect (for psoriasis) and other recently established partner databases for outcomes to COVID-19 in inflammatory diseases (www.covidibd.org and www.rheum-covid.org). We will continue to collaborate closely with these research teams in order to facilitate valuable cross-disease analyses.
SECURE-AD has been endorsed by various societies such as the ETFAD (European Task Force for Atopic Dermatitis), the ISAD (International Society of Atopic Dermatitis), the IEC (International Eczema Council), SPIN (Skin inflammation and Psoriasis International Network), the EADV (European Academy of Dermatology and Venereology), EDEN (European Dermato-Epidemiology Network), the TREAT (TREatment of Atopic Eczema) Registry Taskforce, the ESDR (European Society for Dermatological Research) and the ILDS (International League of Dermatological Societies).
SECURE-AD has been funded by the Irish not-for-profit company NISR (National and International Skin Registry Solutions).